DBV Technologies (DBV) Files BLA for Viaskin Peanut Patch in Children 4—7

DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN Peanut Patch in children aged 4—7 and requested Priority Review. The filing is supported by results from the VITESSE Phase 3 trial.Material DetailsContext by AI AnalystThis is a late-stage regulatory milestone fol…